Absci (ABSI) Cash from Operations (2020 - 2026)
Absci (ABSI) posted Cash from Operations of 26307000.0 for Q1 2026, up 9.85% sequentially from 29182000.0 in Q4 2025, and down 20.46% YoY from 33073431.18 in Q1 2025.
Powered by 
Analysis
Absci (ABSI) Cash from Operations (2020 - 2026) Analysis & Trends
Absci has reported Cash from Operations for 7 years, with the latest figure at 26307000.0 in Q1 2026.
- Quarterly Cash from Operations fell 20.46% year-over-year to 26307000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 97393000.0 (down 27.51% YoY) and the FY2025 annual result came in at 92925000.0, down 28.35% from the prior year.
- Cash from Operations grew to 26307000.0 in Q1 2026 per ABSI's latest filing, from 29182000.0 in the prior quarter.
- Over five years, Cash from Operations peaked at 10361000.0 in Q3 2023 and troughed at 29182000.0 in Q4 2025.
- A 5-year average of 19859352.94 and a median of 19234000.0 in 2023 frame the typical range for Cash from Operations.
- The sharpest annual moves came in 2022 and 2023: Cash from Operations slumped 190.31% in 2022, then surged 45.59% in 2023.
- Over 5 years, Cash from Operations stood at 18568000.0 in 2022, then grew by 19.64% to 14922000.0 in 2023, then dropped by 13.68% to 16964000.0 in 2024, then slumped by 72.02% to 29182000.0 in 2025, then increased by 9.85% to 26307000.0 in 2026.
- According to Business Quant data, Cash from Operations over the past three periods registered 26307000.0, 29182000.0, and 25031000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Operations (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.51 Bn | 130.66 Bn | 2.84 Bn | 1.13 Bn |
| 2 | Regeneron Pharmaceuticals | 85.24 Bn | 77.25 Bn | 3.93 Bn | 813.00 Mn |
| 3 | Argenx Se | 63.46 Bn | 58.28 Bn | 1.37 Bn | - |
| 4 | Moderna | 57.89 Bn | 52.75 Bn | 52.00 Mn | -526.00 Mn |
| 5 | Revolution Medicines | 44.02 Bn | 44.02 Bn | - | -387.32 Mn |
| 6 | BeOne Medicines | 39.95 Bn | 34.85 Bn | 1.53 Bn | 462.82 Mn |
| 7 | Alnylam Pharmaceuticals | 35.49 Bn | 32.19 Bn | 992.69 Mn | 326.72 Mn |
| 8 | Royalty Pharma | 28.43 Bn | 27.59 Bn | - | 728.46 Mn |
| 9 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -88.83 Mn |
| 10 | Absci | 1.38 Bn | 1.18 Bn | - | -27.56 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -27.56 Mn |
| Mar 31, 2026 | -26.31 Mn |
| Dec 31, 2025 | -29.18 Mn |
| Sep 30, 2025 | -25.03 Mn |
| Jun 30, 2025 | -16.87 Mn |
| Mar 31, 2025 | -21.84 Mn |
| Dec 31, 2024 | -16.96 Mn |
| Sep 30, 2024 | -20.73 Mn |
| Jun 30, 2024 | -16.84 Mn |
| Mar 31, 2024 | -17.86 Mn |
| Dec 31, 2023 | -14.92 Mn |
| Sep 30, 2023 | -10.36 Mn |
| Jun 30, 2023 | -19.23 Mn |
| Mar 31, 2023 | -20.12 Mn |
| Dec 31, 2022 | -18.57 Mn |
| Sep 30, 2022 | -19.04 Mn |
| Jun 30, 2022 | -22.58 Mn |
| Mar 31, 2022 | -21.15 Mn |
| Dec 31, 2021 | -17.08 Mn |
| Sep 30, 2021 | -21.75 Mn |